Transcriptional Inactivation of STAT3 by PPARγ Suppresses IL-6-Responsive Multiple Myeloma Cells

Immunity

Volumn 20, Issue 2, 2004, Pages 205-218

  Wang, Li Hua ^a,b   Yang, Xiao Yi ^a   Zhang, Xiaohu ^a   Huang, Jiaqiang ^a   Hou, Jian ^c   Li, Jie ^d   Xiong, Hong ^c   Mihalic, Kelly ^a   Zhu, Heming ^a   Xiao, Weihua ^a   Farrar, William L ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; GW P662; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; PROTEIN INHIBITOR; PROTEIN KINASE B; STAT3 PROTEIN; TROGLITAZONE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CHROMATIN; CONTROLLED STUDY; DNA BINDING; DRUG EFFECT; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MULTIPLE MYELOMA; MYELOMA CELL; PEROXISOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; STATISTICAL SIGNIFICANCE; TRANSACTIVATION; TRANSCRIPTION INITIATION;

EID: 10744226417     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(04)00030-5     Document Type: Article

References (59)

1. Anderson K. Advances in the biology of multiple myeloma. therapeutic applications Semin. Oncol. 26(5 Suppl 13):1999;10-22.
2. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene. 19:2000;2474-2488.
3. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Jr. Stat3 as an oncogene. Cell. 98:1999;295-303.
4. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G.et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 10:1999;105-115.
5. Chung C.D., Lewis L.A., Miceli M.C. T cell antigen receptor-induced IL-2 production and apoptosis have different requirements for Lck activities. J. Immunol. 159:1997;1758-1766.
6. Clark R.B., Bishop-Bailey D., Estrada-Hernandez T., Hla T., Puddington L., Padula S.J. The nuclear receptor PPARγ and immunoregulation. PPARγ mediates inhibition of helper T cell responses J. Immunol. 164:2000;1364-1371.
7. Dankbar B., Padro T., Leo R., Feldmann B., Kropff M., Mesters R.M., Serve H., Berdel W.E., Kienast J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 95:2000;2630-2636.
8. Darnell J.E. Jr. STATs and gene regulation. Science. 277:1997;1630-1635.
9. Debril M.B., Renaud J.P., Fajas L., Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptor γ J. Mol. Med. 79:2001;30-47.
10. Ferlin M., Noraz N., Hertogh C., Brochier J., Taylor N., Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br. J. Haematol. 111:2000;626-634.
11. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans R.M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ Cell. 83:1995;803-812.
12. Gado K., Domjan G., Hegyesi H., Falus A. Role of Interleukin-6 in the pathogenesis of multiple myeloma. Cell Biol. Int. 24:2000;195-209.
13. Giraud S., Bienvenu F., Avril S., Gascan H., Heery D.M., Coqueret O. Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. J. Biol. Chem. 277:2002;8004-8011.
14. Glass C.K., Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14:2000;121-141.
15. Govind A.P., Thampan R.V. Proteins interacting with the mammalian estrogen receptor. proposal for an integrated model for estrogen receptor mediated regulation of transcription J. Cell. Biochem. 80:2001;571-579.
16. Gurnell M., Wentworth J.M., Agostini M., Adams M., Collingwood T.N., Provenzano C., Browne P.O., Rajanayagam O., Burris T.P., Schwabe J.W.et al. A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis. J. Biol. Chem. 275:2000;5754-5759.
17. Hallek M., Bergsagel P.L., Anderson K.C. Multiple myeloma. increasing evidence for a multistep transformation process Blood. 91:1998;3-21.
18. Hirano T., Ishihara K., Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 19:2000;2548-2556.
19. Hideshima T., Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer. 2:2002;927-937.
20. Hideshima T., Nakamura N., Chauhan D., Anderson K.C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 20:2001;5991-6000.
21. Hitzler J.K., Martinez-Valdez H., Bergsagel D.B., Minden M.D., Messner H.A. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood. 78:1991;1996-2004.
22. Hu X., Lazar M.A. Transcriptional repression by nuclear hormone receptors. Trends Endocrinol. Metab. 11:2000;6-10.
23. Huang J., Durum S.K., Muegge K. Cutting edge. histone acetylation and recombination at the TCR gamma locus follows IL-7 induction J. Immunol. 167:2001;6073-6077.
24. Jourdan M., De Vos J., Mechti N., Klein B. Regulation of Bcl-2 family proteins in myeloma cells by three myeloma survival factors. interleukin-6, interferon-alpha and insulin-like growth factor 1 Cell Death Differ. 7:2000;1244-1252.
25. Kastrinakis N.G., Gorgoulis V.G., Foukas P.G., Dimopoulos M.A., Kittas C. Molecular aspects of multiple myeloma. Ann. Oncol. 11:2000;1217-1228.
26. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health and disease. Nature. 405:2000;421-424.
27. Kiuchi N., Nakajima K., Ichiba M., Fukada T., Narimatsu M., Mizuno K., Hibi M., Hirano T. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J. Exp. Med. 189:1999;63-73.
28. Klein B., Zhang X.G., Lu Z.Y., Bataille R. Interleukin-6 in human multiple myeloma. Blood. 85:1995;863-872.
29. Koeffler H.P. Peroxisome proliferator-activated receptor γ and cancers. Clin. Cancer Res. 9:2003;1-9.
30. Li J., Lin Q., Wang W., Wade P., Wong J. Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. Genes Dev. 16:2002;687-692.
31. Liu K.D., Gaffen S.L., Goldsmith M.A. JAK/STAT signaling by cytokine receptors. Curr. Opin. Immunol. 10:1998;271-278.
32. Mitsiades C.S., Mitsiades N., Richardson P.G., Treon S.P., Anderson K.C. Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin. Oncol. 30:2003;309-312.
33. Nikitakis N.G., Siavash H., Hebert C., Reynolds M.A., Hamburger A.W., Sauk J.J. 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells. Br. J. Cancer. 87:2002;1396-1403.
34. Nilsson K., Jernberg H., Pettersson M. IL-6 as a growth factor for human multiple myeloma cells-a short overview. Curr. Top. Microbiol. Immunol. 166:1990;3-12.
35. Padilla J., Leung E., Phipps R.P. Human B lymphocytes and B lymphomas express PPAR-gamma and are killed by PPAR-γ agonists. Clin. Immunol. 103:2002;22-33.
36. Reece D.E. New advances in multiple myeloma. Curr. Opin. Hematol. 5:1998;460-464.
37. Schlezinger J.J., Jensen B.A., Mann K.K., Ryu H.Y., Sherr D.H. Peroxisome proliferator-activated receptor γ-mediated NF-kappa B activation and apoptosis in pre-B cells. J. Immunol. 169:2002;6831-6841.
38. Setoguchi K., Misaki Y., Terauchi Y., Yamauchi T., Kawahata K., Kadowaki T., Yamamoto K. Peroxisome proliferator-activated receptor-γ haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J. Clin. Invest. 108:2001;1667-1675.
39. Shirogane T., Fukada T., Muller J.M., Shima D.T., Hibi M., Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity. 11:1999;709-719.
40. Sjak-Shie N.N., Vescio R.A., Berenson J.R. Recent advances in multiple myeloma. Curr. Opin. Hematol. 7:2000;241-246.
41. Smith M.R., Xie T., Joshi I., Schilder R.J. Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells. Br. J. Haematol. 102:1998;1090-1097.
42. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 79:1994;1147-1156.
43. Treon S.P., Teoh G., Urashima M., Ogata A., Chauhan D., Webb I.J., Anderson K.C. Anti-Estrogens Induce Apoptosis of Multiple Myeloma Cells. Blood. 92:1998;1749-1757.
44. Varterasian M.L. Advances in the biology and treatment of multiple myeloma. Curr. Opin. Oncol. 11:1999;3-8.
45. Wang L.H., Kirken R.A., Yu C.R., Farrar W.L. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J. Immunol. 162:1999;3897-3904.
46. Wang L.H., Yang X.Y., Mihalic K., Xiao W., Li D., Farrar W.L. Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3. J. Biol. Chem. 276:2001;31839-31844.
47. Wang L.H., Yang X.Y., Zhang X., Mihalic K., Xiao W., Farrar W.L. The cis Decoy against the Estrogen Response Element Suppresses Breast Cancer Cells via Target Disrupting c-fos not Mitogen-activated Protein Kinase Activity. Cancer Res. 63:2003;2046-2051.
48. Westendorf J.J., Ahmann G.J., Greipp P.R., Witzig T.E., Lust J.A., Jelinek D.F. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia. 10:1996;866-876.
49. Wolf D., Rodova M., Miska A.E., Calvet P.J., Kouzarides T. Acetylation of β-Catenin by CREB-binding Protein (CBP) J. Biol. Chem. 277:2002;25562-25567.
50. Wright H.M., Clish C.B., Mikami T., Hauser S., Yanagi K., Hiramatsu R., Serhan C.N., Spiegelman B.M. A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation. J. Biol. Chem. 275:2000;1873-1877.
51. Xiao H., Chung J., Kao H.Y., Yang Y.C. Tip60 is a co-repressor for STAT3. J. Biol. Chem. 278:2003;11197-11204.
52. Xu F.H., Sharma S., Gardner A., Tu Y., Raitano A., Sawyers C., Lichtenstein A. Interleukin-6-induced inhibition of multiple myeloma cell apoptosis. support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway Blood. 92:1998;241-251.
53. Yamamoto T., Matsuda T., Junicho A., Kishi H., Saatcioglu F., Muraguchi A. Cross-talk between signal transducer and activator of transcription 3 and estrogen receptor signaling. FEBS Lett. 486:2000;143-148.
54. Yang X.Y., Wang L.H., Chen T., Hodge D.R., Resau J.H., DaSilva L., Farrar W.L. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPARγ) agonists. PPARγ co-association with transcription factor NFAT. J. Biol. Chem. 275:2000;4541-4544.
55. Yang X.Y., Wang L.H., Mihalic K., Xiao W., Chen T., Li P., Wahl L.M., Farrar W.L. Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor γ activated by macrophage-derived 12/15-lipoxygenase ligands. J. Biol. Chem. 277:2002;3973-3978.
56. Yoo J.Y., Wang W., Desiderio S., Nathans D. Synergistic activity of STAT3 and c-Jun at a specific array of DNA elements in the alpha 2-macroglobulin promoter. J. Biol. Chem. 276:2001;26421-26429.
57. Zhang X., Darnell J.E. Jr. Functional importance of Stat3 tetramerization in activation of the alpha 2-macroglobulin gene. J. Biol. Chem. 276:2001;33576-33581.
58. Zhang Z., Jones S., Hagood J.S., Fuentes N.L., Fuller G.M. STAT3 acts as a co-activator of glucocorticoid receptor signaling. J. Biol. Chem. 272:1997;30607-30610.
59. Zhong Z., Wen Z., Darnell J.E. Jr. Stat3. a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6 Science. 264:1994;95-98.